Apart from confirming that patients with Parkin mutations had more severe l-dopa–induced dyskinesia, no consistent phenotypic difference was identified between mutation-positive and mutation-negative subtypes at a single time point. The gene discussed is PRKN; the disease is drug-induced dyskinesia.